Last reviewed · How we verify
Once-daily Insulin
Once-daily insulin replaces or supplements the body's natural insulin production to regulate blood glucose levels by facilitating glucose uptake into cells and promoting glycogen synthesis.
Once-daily insulin replaces or supplements the body's own insulin production to regulate blood glucose levels by promoting glucose uptake into cells and storage as glycogen. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Once-daily Insulin |
|---|---|
| Sponsor | Hospital Universitario Dr. Jose E. Gonzalez |
| Drug class | Long-acting insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin is a peptide hormone that binds to insulin receptors on cell surfaces, enabling glucose transport from the bloodstream into muscle, fat, and liver cells. Once-daily formulations use extended-release technology to provide sustained insulin levels throughout the day, reducing the frequency of injections needed for glycemic control in diabetes management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- Effects of Cofrogliptin on Beta-Cell Function in LADA Patients (NA)
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity (PHASE4)
- Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS (NA)
- Empagliflozin Adjunctive Therapy in Bipolar Depression (NA)
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
- Evaluating the SWW Method Dietary Intervention for HbA1c and Weight Management as a Preventative Intervention in Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Once-daily Insulin CI brief — competitive landscape report
- Once-daily Insulin updates RSS · CI watch RSS
- Hospital Universitario Dr. Jose E. Gonzalez portfolio CI